Structural Biology Market (By Tools: SaaS and Standalone Modeling, Visualization and Analysis, Others; By Application: Drug Development, Drug Discovery, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
The global structural biology market is surging, with an overall revenue growth expectation of hundreds of millions of dollars during the forecast period from 2023 to 2032.
To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics
Structural biology is a scientific discipline that focuses on studying the three-dimensional shapes and spatial arrangements of biological molecules and macromolecules, such as proteins, nucleic acids and carbohydrates. This field aims to understand the atomic-level details of these molecules' structures and how their shapes relate to their functions and interactions within living organisms. By determining the precise arrangement of atoms in these biomolecules, structural biology provides insights into the molecular mechanisms underlying various biological processes and diseases.
The methods used in structural biology include techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, electron microscopy, and computational modelling. These methods enable researchers to visualize and analyze the shapes of biomolecules in various states, such as at rest, during interactions with other molecules, or when bound to potential drugs.
Growth Factors:
The information obtained through structural biology studies contributes to a deeper understanding of biological processes, aiding in the development of new drugs, therapies, and treatments for various diseases. The market is driven by several factors including technological advancements, drug discovery and development, the rise of structural genomics, growing government and private funding and increasing collaboration and partnership.
| Report Coverage | Details |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Tools and By Application |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver:
Growing prevalence of chronic disease
Chronic medical conditions instances are rising due to people's unhealthy habits these days and the ageing of the population in industrialized nations. These diseases including diabetes, cancer, heart disease, and others are becoming more common. The fields of medicine and healthcare benefit greatly from structural biology, which aids in the discovery of treatment options for a variety of diseases. Thus, the factor driving this market is the rise in chronic disease cases brought on by bad lifestyle choices.
For instance, according to the International Diabetes Federation, there are 537 million individuals (20–79 years old) who have diabetes in 2021. By 2030, there will be 643 million individuals worldwide with diabetes, and by 2045, there will be 783 million. Thus, the aforementioned facts drive the market growth during the forecast period.
Restraint:
Cost and complexity of techniques
The high resolution of structural biology techniques often requires expensive equipment and dedicated facilities. The initial costs of setting up and maintaining these facilities can be a barrier for some research institutions and organizations, particularly in resource-constrained environments. In addition, many of the techniques used in structural biology, such as X-ray crystallography and NMR spectroscopy, require specialized expertise and equipment. The complexity of these techniques can limit their accessibility to researchers without specific training, hindering wider adoption and advancements. Thus, the cost and complexity of techniques are expected to hinder market growth during the forecast period.
Opportunity:
Technological advancements
Technological innovations in the fields such as X-ray crystallography, nuclear magnetic resonance spectroscopy, and electron microscopy have enabled researchers to visualize and analyze biomolecular structures with higher resolution and accuracy. These advancements have expanded the capabilities of structural biology and opened up new avenues for research.
For instance, in June 2023, the world leader in X-ray diffraction, Bruker Corporation, introduced the D6 PHASERTM X-Ray Diffraction (XRD) system. A brand-new benchtop XRD platform called D6 PHASER was created with analytical versatility that is usually reserved for bigger, floor-standing systems. The D6 PHASER extensive feature set will make it possible for more XRD applications for new user communities and markets. Thus, this kind of product innovation is expected to provide an attractive opportunity for market growth during the forecast period.
Based on the tools, the SaaS and standalone modeling segment is expected to capture the largest market share over the forecast period. SaaS platforms offer cloud-based solutions that enable researchers to access and use structural biology software and tools remotely via the Internet. These platforms often provide user-friendly interfaces, data storage, and collaboration features. SaaS solutions are particularly valuable for researchers who may not have access to high-performance computing resources or specialized software in their local laboratories.
They also enable real-time collaboration and data sharing among researchers across different locations. Besides, standalone modelling software refers to software applications that are installed on local computers or workstations. These software packages offer advanced tools for analyzing, modelling and simulating biomolecular structures. Researchers often use standalone software for in-depth structural analysis, molecular docking studies, molecular dynamics simulations, and more. These tools provide greater customization and flexibility for researchers with specific computational requirements. Thus, this is expected to propel the market growth during the forecast period.
Based on the application, the global structural biology market is segmented into drug development, drug discovery and others. The drug discovery segment is expected to grow significantly during the forecast period. Drug discovery by structural biology involves leveraging the three-dimensional structures of biomolecules, particularly proteins, to design and develop novel drugs. Structural biology provides insights into the atomic-level details of how proteins function, interact with other molecules, and contribute to various disease processes.
Structural biology techniques, such as X-ray crystallography and NMR spectroscopy, help determine the 3D structures of proteins implicated in diseases. These structures provide valuable information about the active sites and binding pockets of the proteins, which can be potential targets for drug intervention. Structural data allow researchers to design drugs with specific shapes and chemical features that complement the target protein's binding site. This approach, known as structure-based drug design, enhances the likelihood of successful drug-target interactions. Thereby, driving the segment growth during the forecast period.
North America is expected to dominate the market over the forecast period. The market growth is driven by the growing chronic disease and increasing geriatric population. Moreover, North America is home to several world-renowned universities, research centers, and academic institutions that actively engage in structural biology research. These institutions contribute to both basic research and applied studies, fostering collaborations and advancing the field.
Furthermore, the pharmaceutical and biotechnology industries in North America have been at the forefront of utilizing structural biology in drug discovery and development. Structural insights into drug targets help in designing more effective and targeted therapies, contributing to the region's robust pharmaceutical sector. For instance, the average percentage of personal income in the US that is spent on medications is around 3.67%.
According to US pharmaceutical industry data, by 2023, US pharmaceutical businesses are expected to increase at a compound annual growth rate (CAGR) of 3.5%. The anticipated growth rate for enterprises that manufacture generic pharmaceuticals is 0.8%. Therefore, the aforementioned fact is expected to propel the structural biology market in the region during the forecast period.
Asia Pacific is expected to grow at the highest CAGR during the forecast period. Asia Pacific is home to a growing number of research institutions and universities that are actively engaged in structural biology research. These institutions contribute to both local and global scientific advancements. Moreover, the region has witnessed the expansion of its biotechnology and pharmaceutical sectors, leading to increased demand for structural biology expertise in drug discovery and development.
India is one of the world's largest exporters of pharmaceuticals, with shipments to more than 200 nations. More than half of Africa's generic needs are met by India, which also provides around 40% of US generic demand and 25% of UK pharmaceutical need. Approximately 60% of the world's vaccination demand is met by India, which is also a major provider of the DPT, BCG, and measles vaccines. As per the essential immunization schedule, India supplies 70% of the vaccines used by the WHO. Thus, this is expected to drive market growth during the forecast period.
Segments Covered in the Report:
By Tools
By Application
By Geography
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
